[{"id":"3256127a-0abe-4b2e-b192-b4bbda0ec654","acronym":"","url":"https://clinicaltrials.gov/study/NCT01594723","created_at":"2021-01-18T06:48:50.034Z","updated_at":"2024-07-02T16:35:13.492Z","phase":"Phase 2","brief_title":"A Study of LY2784544 in Participants With Myeloproliferative Neoplasms","source_id_and_acronym":"NCT01594723","lead_sponsor":"Eli Lilly and Company","biomarkers":" JAK2","pipe":" | ","alterations":" JAK2 V617F • JAK2 mutation","tags":["JAK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JAK2 V617F • JAK2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gandotinib (LY 2784544)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 110","initiation":"Initiation: 05/22/2012","start_date":" 05/22/2012","primary_txt":" Primary completion: 03/20/2015","primary_completion_date":" 03/20/2015","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-03-21"},{"id":"0659227f-d0fb-4536-839e-0b6d4a52a25d","acronym":"","url":"https://clinicaltrials.gov/study/NCT01134120","created_at":"2021-01-18T04:30:30.495Z","updated_at":"2024-07-02T16:37:11.464Z","phase":"Phase 1","brief_title":"A Study in Myeloproliferative Disorders","source_id_and_acronym":"NCT01134120","lead_sponsor":"Eli Lilly and Company","biomarkers":" JAK2","pipe":" | ","alterations":" JAK2 V617F • JAK2 mutation","tags":["JAK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JAK2 V617F • JAK2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gandotinib (LY 2784544)"],"overall_status":"Completed","enrollment":" Enrollment 80","initiation":"Initiation: 04/01/2010","start_date":" 04/01/2010","primary_txt":" Primary completion: 04/01/2014","primary_completion_date":" 04/01/2014","study_txt":" Completion: 02/22/2018","study_completion_date":" 02/22/2018","last_update_posted":"2018-04-17"}]